Intel Introduces Core Series 2 Processor, Expands Edge AI Portfolio

Intel has unveiled a new industrial-ready processor platform tailored for real-time edge workloads, in addition to a healthcare-focused AI development suite. The company made these announcements at embedded world 2026 in Nuremberg, underscoring its increasing emphasis on edge computing and AI-enabled applications.

For engineers and developers engaged in edge systems, this news signifies the introduction of new hardware and software tools geared towards deterministic industrial control and AI-driven healthcare monitoring. Intel aims to streamline complex edge architectures with its latest offerings, facilitating quicker innovation across various sectors.

Core Series 2: Enhancing Industrial Real-Time Performance

The new Intel Core Series 2 processors featuring P-cores are positioned as an industrial platform for mission-critical edge applications, where timing precision and reliability are paramount. These environments often demand processors capable of handling multiple critical workloads concurrently, such as safety systems, control loops, and real-time analytics.

Traditional processors frequently necessitate designers to compromise between computational performance and deterministic behavior, often steering developers towards multi-processor architectures. Intel asserts that the new Core Series 2 aims to eliminate this trade-off.

When compared with AMD’s Ryzen 7 9700X, Intel claims that the new processors offer up to 4.4x lower maximum PCIe latency, up to 2.5x more deterministic response time, and up to 3.8x better deterministic performance. Multi-thread performance is also purported to improve by as much as 1.5x.

“Intel continues to lead in edge computing, which remains one of our fastest-growing business segments,” stated Dan Rodriguez, Intel corporate vice president and general manager of the Edge Computing Group. ” With the introduction of Core Series 2, our CES launch of Core Ultra Series 3, and our expanding Edge AI Suites, we continue to deliver comprehensive platforms that meet diverse edge customer needs with breakthrough performance, reliability, and integrated AI acceleration.”

These processors are designed for use in industrial automation, robotics, machine vision, and other applications where deterministic performance and predictable latency are critical.

Healthcare AI Suite: Focused on Patient Monitoring

Concurrently with the processor launch, Intel provided a sneak peek of a new Edge AI Suite for Health & Life Sciences. This software package offers validated reference pipelines and benchmarking tools for developers constructing AI-powered patient monitoring systems.

Healthcare settings are progressively adopting connected monitoring systems that integrate multiple sensors and AI algorithms. Intel’s suite showcases various multimodal workloads running locally on its processors, including AI-based ECG arrhythmia detection, remote photoplethysmography, and anonymous 3D visual tracking.

Instead of relying on synthetic benchmarks, the company asserts that the suite empowers OEMs, ODMs, and independent software vendors to evaluate hardware platforms using realistic healthcare scenarios.

This new AI suite complements Intel’s broader edge portfolio, which now encompasses the recently launched Core Ultra Series 3 processors and the new Core Series 2 family. Together, these platforms aim to support both deterministic industrial control and advanced AI acceleration at the edge.

Systems based on Core Ultra Series 3 and Core Series 2 processors are currently available, while a preview version of the Health & Life Sciences Edge AI suite is accessible on GitHub. General availability is slated for the second quarter of 2026.